Doesn't look like good news to the markets |
Over £16 @ the open? |
Nice to see a court case win, as it was news of these collective challenges that sent the share price heading south from 1800..Looks like the wider market is on for a rebound too after the sell off Friday/Monday, could be an interesting day.. :o) |
Seems like good news.. |
Crazy disparity but I suppose Barclays is nearer the average consensus |
Barclays cuts target price to 1650p from 1725p. Bernstein raises target price to 2610p from 2560p ...??! |
 From the IC.At first sight, the market seemed to shrug off what were objectively decent results for drugmaker GSK (GSK) as the now pure play pharmaceutical company finds its feet and restocks what had become a threadbare research & development pipeline. Getting more value out of hard-to-copy medicines is a priority for GSK, and one where it lags its highly valued competitor AstraZeneca (AZN), but first it has a battalion of troubles to deal with. It is the state of litigation which has given investors a dyspeptic ulcer. The prospect of the company facing long rounds of litigation over its Zantac reflux medicine, with suits alleging its cancer-causing properties having been filed in numerous jurisdictions, was enough to crash the shares earlier this year the main problem being the currently unquantifiable cost of the saga.There is nothing new to report on this front, other than the company's legal costs in relation to this topic have increased, although it does not break these out of the cost of individual litigation.Unsurprisingly, chief executive Dame Emma Walmsley was keen to accentuate the positive: "Sales grew in all areas, with speciality medicines in particular benefiting from new product launches in oncology and HIV. In R&D, so far this year, we have secured approvals or filings for 10 major opportunities and reported positive data from seven phase III trials".RSV jab restrictions heap more uncertainty on GSKThe company's core reported operating profits, which strips out inconvenient costs such as litigation to which pharmaceutical companies are notoriously vulnerable, were 16 per cent higher for the half at £4.95bn. This was marginally ahead of consensus forecasts, which meant an upgrade in expectations for operating profit growth to a range 11 to 13 per cent.However, the market also seemed to cotton to GSK's higher contingent liability charges of £1.06bn, compared with a credit of £0.46bn last year. Fair value losses of £35mn were booked for GSK's ongoing share of its Haleon spin-out, as well to reflect the longer-term prospects for its vaccines business and various milestones that it will need to pay its development partners.In addition to its woes, Deutsche Bank points out that there are questions over how effectively GSK can bridge the patent cliff for its HIV medicine Dolutegravir. The shares have performed poorly since our buy tip in May, but the consensus PE of 13 offers a margin of safety compared with pricier pharma companies. Buy. |
Safe haven stock in a recession though |
Doing well so far but US about to open... Will it pare back?! |
Ignore broker ratings for this stock. |
Pick 'n' mix in the broker ratings today...
Stifel raises GSK price target to 1,770 (1,740) pence - 'hold'
DZ Bank cuts fair value for GSK to 1,650 (1,750) pence - 'hold'
JPMorgan cuts GSK price target to 1,550 (1,660) pence - 'underweight' |
That is very good news both for GSK and future patients |
A very nice bit of news here this morning.
Buying just under / just above 1500 seems money well spent here in my opinion.
Good luck all 👍🏻 |
hTTps://www.londonstockexchange.com/news-article/GSK/fda-expands-jemperli-approval/16599392 |
Deutsche bank cuts target price to 1850p from 1950p |
Pleased I sold at £15.50.abd got my money back (10k investment) . Will wait till it falls to high £14 and buy back in as I still think it can get above £17 |
In the real world GSK have more than replaced those lost sales and shall replace them further going forward.These analysts consistently leave you saying WTF |
Citi analyst Peter Verdult said while second quarter revenue and adjusted EPS beat expectations by 5% and 12% respectively, and full year guidance was raised, "we anticipate investor focus to fall on the lowered expectations for the vaccines division as a result of uncertainty around the target Arexvy patient population in the US following the June [Advisory Committee on Immunization Practices] meeting and slowing US Shingrix momentum."
"The vaccines portfolio was weaker, missing consensus by 9%," he noted while Shingrix missed by 20%, driven by weakness in the US. |
Overall excellent growth. The market at times acts like a petulant child as times. And only looks at the slight negatives rather than the 95% positives... |
Another 1.4k for me at 15.09ish.
Seems an overdone fall to me on good results as far as i can tell. Anyhow, anther 900 quid income addition. I get fa interest in cash in my isa, and somehow i have a lot of cash.
A reasonable income stream addition, with the real probability of increasing share price over whatever timescale it takes. It's only this cheap due to us litigation, so a bit of a gamble on that. But it'll eventually sort itself out. |
TM,I am doing the same but in round about way,nudge nudge, wink wink ! |
I'm building a significant stake in the company ...... ;0) |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
